Polyembo
Polyembo is a pre-commercial medical device company developing the SCRUNCHY® nitinol vascular embolization platform, targeting hospitals and interventional radiology departments with a two-SKU system designed to replace multi-device embolization procedures.
- Company typePrivate
- Founded2022
- HeadquartersLongmont, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Polyembo does
Polyembo, Inc. is a U.S.-based, privately held medical device company founded in 2022 and headquartered in Longmont, Colorado. It is developing a portfolio of vascular embolization devices for the interventional radiology and vascular surgery market, anchored by the SCRUNCHY® platform, a nitinol-frame embolic device delivered through a 0.027" microcatheter that uses laser-cut construction, fiber fill, thermal shape setting, and integrated marker bands. The platform is offered in two SKUs (SCY-6-P for 2-6mm vessels and SCY-9-D for 5-9mm vessels) and is designed to achieve vessel occlusion in under three minutes with a ~1 cm landing zone, positioned against incumbent vascular plugs and standard microcoils.
Two additional products, Sphere and PuffyCoil, are listed as under development, expanding the portfolio beyond the lead device. All Polyembo devices are investigational: they have not been cleared by the FDA or approved in any market and are not available for sale. The company is therefore pre-commercial and pre-revenue, with monetization contingent on regulatory clearance followed by direct enterprise sales to hospitals and interventional radiology departments, the standard go-to-market model for embolization devices.
The company is led by CEO John Crowley, formerly VP and Franchise GM of Interventional Oncology at Boston Scientific (29 years), with DJ Ashurst (Senior Director; nitinol platform and FDA clearance experience) and Dean Carpenter (Director of Engineering; med-device manufacturing scale-up). In October 2025, Polyembo closed a funding round led by an undisclosed multinational strategic investor to advance product development and pursue regulatory clearance. Trademark protection has been filed for the SCRUNCHY® brand.
Polyembo firmographics
Firmographics- Name
- Polyembo
- Legal name
- Polyembo Inc
- Website
- https://polyembo.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Polyembo is a pre-commercial medical device company developing the SCRUNCHY® nitinol vascular embolization platform, targeting hospitals and interventional radiology departments with a two-SKU system designed to replace multi-device embolization procedures.
- Ownership category
- akta.pro rank
Polyembo industry classification
Industry- Product category
- Vascular Embolization Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)
Keywords
Where Polyembo is headquartered
LocationHeadquarters
- HQ city
- Longmont
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Polyembo business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Medical Device Sales: Pre-commercial stage. The company is developing vascular embolization devices (SCRUNCHY, Sphere, PuffyCoil) for sale to hospitals and interventional radiology departments. Products are not yet approved for marketing in the US or any markets. Revenue will be generated through direct device sales once regulatory clearance is obtained.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Polyembo product offering
Product offeringCore offering
Polyembo develops and manufactures vascular embolization medical devices, with the SCRUNCHY platform as its lead product. The SCRUNCHY device is a nitinol-based embolic implant delivered through a 0.027" microcatheter to occlude vessels ranging from 2-9mm using only two device sizes (SCY-6-P and SCY-9-D). Additional products Sphere and PuffyCoil are in development as part of the company's embolic technology portfolio. All devices are currently investigational and not approved for sale in any market.
Product overview
Polyembo is a medical device company (established 2022) specializing in vascular embolization technologies. The company's product portfolio includes the SCRUNCHY platform as its lead product, along with Sphere and PuffyCoil — all designed to address inventory complexity in vessel embolization procedures. The SCRUNCHY platform is the primary offering, featuring a nitinol frame-based embolic device delivered through microcatheters for 2-9mm vessel treatment, while Sphere and PuffyCoil represent additional products in development to expand the company's embolization technology suite. The devices are currently investigational and not approved for sale in any markets.
Differentiator
Problem solved
Functional benefit
Brands
- SCRUNCHY: Next-generation vascular embolic device platform designed to be the most versatile embolization system available, engineered for physicians' needs. Delivered through a microcatheter system offering the widest range of vessel treatment (2-9mm vessels with only 2 SKUs). Available in Pushable and Detachable versions.
Products and services
- SCRUNCHY Vascular Embolic Device Next-generation vascular embolic device platform designed for vessel occlusion in 2-9mm vessels using only two SKUs (SCY-6-P for 2-6mm vessels and SCY-9-D for 5-9mm vessels). Features a nitinol frame with laser-cut construction, fiber fill, and thermally shape-set design with integrated marker bands. Delivered through a 0.027" ID microcatheter with self-anchoring, retractable deployment. Will be offered in Pushable and Detachable versions. Intended for interventional radiologists and vascular surgeons performing embolization procedures.
- Sphere Vascular embolization product under development as part of Polyembo's portfolio of embolic technologies, expanding the company's embolization device suite beyond the SCRUNCHY platform.
- PuffyCoil Vascular embolization product under development as part of Polyembo's portfolio of embolic technologies, intended to complement the SCRUNCHY platform in addressing vessel occlusion procedures.
Quantifiable outcome
- 85% SKU reduction compared to existing embolization solutions
- +3 more outcomes
Companies that use Polyembo
Customer profileSegments1 record
Ideal customer profiles1 record
Polyembo technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Polyembo partnerships and signals
Strategic signalScale indicators5 records
Recent moves5 records
Expansion highlights5 records
Polyembo competitors and assessment
Company assessmentBroad incumbents
- Medtronic: Medtronic is a broad incumbent with vascular embolization products across its peripheral vascular and neurovascular franchises, competing with Polyembo across multiple potential indications.
- Stryker: Stryker's neurovascular division offers coil-based embolization products (Target XL) and competes in the broader vascular occlusion space, including potential cross-sell into peripheral indications.
- Boston Scientific: Boston Scientific has an interventional oncology and peripheral embolization portfolio (including Embozene microspheres) and is a broad incumbent in the space. Polyembo's CEO previously spent 29 years there, including leading its interventional oncology franchise.
Direct peers
- Penumbra: Penumbra is a direct competitor in vascular embolization, offering coil and embolization products (e.g., Ruby Coil, LANTERN) targeting interventional radiologists and vascular surgeons — the same specialty customer base as Polyembo.
- Kaneka: Kaneka offers peripheral embolization products (e.g., embolization coils and plugs) targeting interventional radiology procedures, directly comparable to Polyembo's SCRUNCHY platform in vessel occlusion applications.
- Terumo: Terumo's AZUR peripheral embolization coil system competes directly with Polyembo's SCRUNCHY for vascular occlusion procedures in the same target vessel sizes and clinical settings.
- Cook Medical: Cook Medical is a direct peer offering embolization coils and plugs (e.g., MRE coils) sold to interventional radiologists and vascular surgeons, competing directly with Polyembo in the peripheral vascular occlusion market.
- Merit Medical: Merit Medical offers Embosphere microspheres and other embolization products for peripheral vascular occlusion. It directly competes for hospital IR department business and contracts.
Emerging players
- Sirtex Medical: Sirtex develops SIR-Spheres radioembolization technology for interventional oncology, overlapping with Polyembo's longer-term oncology embolization applications and IR customer base.
- Embolx: Embolx is an emerging player developing microcatheter-based embolization delivery technologies for targeted vascular occlusion, addressing overlapping use cases in interventional oncology and peripheral embolization.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Polyembo social profiles
Digital presencePolyembo financial estimates
Financial estimateRevenue estimate
Valuation estimate
Polyembo leadership team
Management profileNumber of profiles
Profiles3 records
Polyembo funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Polyembo M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Polyembo
What does Polyembo do?
Polyembo develops and manufactures vascular embolization medical devices, with the SCRUNCHY platform as its lead product. The SCRUNCHY device is a nitinol-based embolic implant delivered through a 0.027" microcatheter to occlude vessels ranging from 2-9mm using only two device sizes (SCY-6-P and SCY-9-D). Additional products Sphere and PuffyCoil are in development as part of the company's embolic technology portfolio. All devices are currently investigational and not approved for sale in any market.
Is Polyembo a public or private company?
Polyembo is a private company. It is classified as venture growth investor backed and is currently operating.
When was Polyembo founded?
Polyembo was founded in 2022. It employs 1 to 10 people.
Where is Polyembo based?
Polyembo is headquartered in Longmont, United States, in the North America region.
How does Polyembo make money?
One revenue line is on record: medical Device Sales.
Who are Polyembo's main competitors?
Broad incumbents on record are Medtronic, Stryker and Boston Scientific. Direct peers are Penumbra, Kaneka, Terumo, Cook Medical and Merit Medical. Emerging players are Sirtex Medical and Embolx.
Does Polyembo have an API?
No public API is recorded for Polyembo.
What industry is Polyembo in?
Polyembo's product category is Vascular Embolization Medical Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices. Its NAICS code is 339112 and its SIC code is 3841.